Roche's Hostile Bid for Ventana Passes Federal Antitrust Hurdle | GenomeWeb
NEW YORK (GenomeWeb News) — The US federal anti-trust waiting period has passed on Roche’s hostile takeover bid for Ventana Medical Systems, Roche said today.
  
The expiration of the Hart-Scott-Rodino waiting period satisfies one condition of Roche’s offer, under which it would buy all of Ventana’s outstanding shares for $75 in cash per share, or $3 billion.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.